Genomic Tests

Comprehensive Genomic Profiling using Next-Generation Sequencing with Machine/deep Learning

Next Generation Sequencing DNA & RNA Testing

Next Generation Sequencing DNA & RNA Testing

Solid Tumors

Liquid Trace™:

Solid Tumor Profile
302 / >1600
DNA / RNA Genes
  • TAT


    5-7 Days
  • Indications


    All solid tumors Chromosomal abnormalities, gene amplifications, HRR
    Fusions: ALK, ROS1, RET,
    NTRK1/2/3, and more.
    BRAF, CIC, EWSR1, PD-L1,
    MET exon 14 skipping
    and various alternative splicing,
    MET, HER2, PIK3CA, PTEN,
    Gene amplifications, AKT1, RAS,
    HER2, MYC, EGFR, TTV,
    T- & B-cell clonality analysis
    Monitor therapeutic response

  • Sample Type

    Peripheral blood
  • Sample Requirements


    Peripheral blood: 8-10 ml.
    EDTA tube preferred
    CSF: 7-10 mL. Clear tubes
  • Results Reported

    DNA+RNA
  • Monitoring
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Solid Tumor

Profile Plus™
434 / >1600
DNA / RNA Genes
  • TAT


    7-10 Days
  • Indications


    All solid tumors
    Fusions: ALK, ROS1, RET,
    NTRK1/2/3, and more.
    BRAF, CIC, EWSR1, PD-L1,
    MET exon 14 skipping
    and various alternative splicing, MET, HER2, EGFR,
    Gene amplifications, PIK3CA, PTEN, TTV,
    AKT1, RAS and HRD
    Cancer of unknown primary (CUP)
    T- & B-cell clonality analysis


  • Sample Type

    FFPE
  • Sample Requirements


    1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    DNA+RNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Solid Tumor

Profile™
434
DNA Genes
  • TAT


    5-7 Days
  • Indications


    All solid tumors:
    Mutations in 434 genes, copy number
    variation and chromosomal structural
    abnormalities, TMB, MSI, HRD








  • Sample Type

    FFPE
  • Sample Requirements


    1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    DNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Solid Tumor Fusion / Expression Profile

>1600
RNA Genes
  • TAT


    7-10 Days
  • Indications


    All Solid tumors:
    Fusion: ALK, ROS1, RET, BRAF,
    NTRK1/2/3, FGFR1/2/3/4, CIC,
    EWSR1 & other sarcoma genes
    Expression: PD-L1, MYC, CCND1,
    MET, FGFR1/2/3/4, Ki67, ERBB2, MDM2
    Alternative splicing: MET exon 14
    skipping, EGFRvIII, NTRK,
    Mutations in more than 1600 genes, TTV,
    T- & B-cell clonality analysis


  • Sample Type

    FFPE
  • Sample Requirements


    1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    RNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Hematology

Liquid Trace™:

Hematology Profile
302 / >1600
DNA / RNA Genes
  • TAT


    5-7 Days
  • Indications


    All hematologic neoplasms
    including lymphoma
    multiple myeloma, acute lymphoblastic leukemia,
    acute myeloid leukemia,
    MDS, TTV, CMML, MPN,
    VEXAS syndrome, and EBV
    Chromosomal abnormalities, and gene amplifications,
    T- & B-cell clonality analysis
    Monitor therapeutic response

  • Sample Type



    Peripheral blood
  • Sample Requirements




    Peripheral blood: 8-10 ml.
    EDTA tube preferred
    CSF: 7-10 mL. Clear tubes
  • Results Reported

    DNA+RNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Hematology

Profile Plus™
302 / >1600
DNA / RNA Genes
  • TAT


    7-10 Days
  • Indications


    All hematologic neoplasms including lymphoma
    Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia
    Includes IgVH
    Chromosomal abnormalities, and gene amplifications, TTV,
    T- & B-cell clonality analysis


  • Sample Type

    Bone marrow,
    Peripheral blood,
    Fresh tissue
  • Sample Requirements

    Bone marrow: 2ml.
    Peripheral blood: 5 ml.
    EDTA tube preferred
    FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    DNA+RNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Hematology

Profile™
302
DNA Genes
  • TAT


    5-7 Days
  • Indications


    All hematologic neoplasms
    including lymphoma
    MDS, CMML, AML, MPN (JAK2, CALR, MPL),
    MRD, multiple myeloma, and other
    hematologic diseases






  • Sample Type

    Bone marrow,
    Peripheral blood,
    Fresh tissue
  • Sample Requirements

    Bone marrow: 2ml.
    Peripheral blood: 5 ml.
    EDTA tube preferred
    FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    DNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching